66 related articles for article (PubMed ID: 10079468)
1. Chronic myelogenous leukemia: update on biology and treatment.
Faderl S; Kantarjian HM; Talpaz M
Oncology (Williston Park); 1999 Feb; 13(2):169-80; discussion 181, 184. PubMed ID: 10079468
[TBL] [Abstract][Full Text] [Related]
2. Chronic myeloid leukemia with a significant increase of monocytes and rare karyotype: A case report and literature review.
Zhang Y; Tan Q; Cao P; Chen C; Chen W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 46(3):322-327. PubMed ID: 33927081
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloid leukemia: Relevance of cytogenetic and molecular assays.
Bennour A; Saad A; Sennana H
Crit Rev Oncol Hematol; 2016 Jan; 97():263-74. PubMed ID: 26412717
[TBL] [Abstract][Full Text] [Related]
4. Bacillamide F, Extracted from Marine
Zhang S; Croppi G; Hu H; Li Y; Zhu C; Wu F; Zhang F; Li Z
Biology (Basel); 2022 Nov; 11(12):. PubMed ID: 36552221
[TBL] [Abstract][Full Text] [Related]
5. Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study.
Pungolino E; D'adda M; De Canal G; Trojani A; Perego A; Elena C; Lunghi F; Turrini M; Borin L; Iurlo A; Latargia ML; Carraro MC; Spina F; Artale S; Anghilieri M; Molteni A; Caramella M; Baruzzo G; Nichelatti M; Di Camillo B; Cairoli R
Eur J Haematol; 2021 Oct; 107(4):436-448. PubMed ID: 34139044
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy.
Shao Y; Luo W; Guo Q; Li X; Zhang Q; Li J
Drug Des Devel Ther; 2019; 13():2043-2055. PubMed ID: 31388296
[No Abstract] [Full Text] [Related]
7. Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia.
Bettiol A; Marconi E; Lombardi N; Crescioli G; Gherlinzoni F; Walley T; Vannacci A; Chinellato A; Giusti P
Clin Drug Investig; 2018 Sep; 38(9):837-844. PubMed ID: 30043130
[TBL] [Abstract][Full Text] [Related]
8. Long-term adjuvant treatment of gastrointestinal stromal tumors (GIST) with imatinib-a comment and reflection on the PERSIST-5 study.
Cameron S
Transl Gastroenterol Hepatol; 2018; 3():16. PubMed ID: 29682623
[No Abstract] [Full Text] [Related]
9. Inhibition of Siah2 Ubiquitin Ligase by Vitamin K3 Attenuates Chronic Myeloid Leukemia Chemo-Resistance in Hypoxic Microenvironment.
Huang J; Lu Z; Xiao Y; He B; Pan C; Zhou X; Xu N; Liu X
Med Sci Monit; 2018 Feb; 24():727-735. PubMed ID: 29400343
[TBL] [Abstract][Full Text] [Related]
10. Encapsulation of
Mendes AN; Filgueiras LA; Siqueira MRP; Barbosa GM; Holandino C; de Lima Moreira D; Pinto JC; Nele M
Int J Nanomedicine; 2017; 12():8363-8373. PubMed ID: 29200848
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 3- receptor targeted exosomes inhibit
Bellavia D; Raimondo S; Calabrese G; Forte S; Cristaldi M; Patinella A; Memeo L; Manno M; Raccosta S; Diana P; Cirrincione G; Giavaresi G; Monteleone F; Fontana S; De Leo G; Alessandro R
Theranostics; 2017; 7(5):1333-1345. PubMed ID: 28435469
[TBL] [Abstract][Full Text] [Related]
12. Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey.
Yildiz I; Yokuş O; Gedik H
Avicenna J Med; 2017; 7(1):28-31. PubMed ID: 28182037
[TBL] [Abstract][Full Text] [Related]
13. Chronic Myeloid Leukemia in Nigerian Patients: Anemia is an Independent Predictor of Overall Survival.
Oyekunle AA; Durosinmi MA; Bolarinwa RA; Owojuyigbe T; Salawu L; Akinola NO
Clin Med Insights Blood Disord; 2016; 9():9-13. PubMed ID: 27375361
[TBL] [Abstract][Full Text] [Related]
14. Determinants of Overall and Progression-Free Survival of Nigerian Patients with Philadelphia-Positive Chronic Myeloid Leukemia.
Oyekunle AA; Bolarinwa RA; Oyelese AT; Salawu L; Durosinmi MA
Adv Hematol; 2015; 2015():908708. PubMed ID: 26435715
[TBL] [Abstract][Full Text] [Related]
15. Dual effect of oxidative stress on leukemia cancer induction and treatment.
Udensi UK; Tchounwou PB
J Exp Clin Cancer Res; 2014 Dec; 33():106. PubMed ID: 25519934
[TBL] [Abstract][Full Text] [Related]
16. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.
Hirji I; Gupta S; Goren A; Chirovsky DR; Moadel AB; Olavarria E; Victor TW; Davis CC
Health Qual Life Outcomes; 2013 Oct; 11():167. PubMed ID: 24099272
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines?
Rumjanek VM; Vidal RS; Maia RC
Biosci Rep; 2013 Nov; 33(6):. PubMed ID: 24070327
[TBL] [Abstract][Full Text] [Related]
18. Semi-supervised prediction of SH2-peptide interactions from imbalanced high-throughput data.
Kundu K; Costa F; Huber M; Reth M; Backofen R
PLoS One; 2013; 8(5):e62732. PubMed ID: 23690949
[TBL] [Abstract][Full Text] [Related]
19. Induction of cellular senescence by doxorubicin is associated with upregulated miR-375 and induction of autophagy in K562 cells.
Yang MY; Lin PM; Liu YC; Hsiao HH; Yang WC; Hsu JF; Hsu CM; Lin SF
PLoS One; 2012; 7(5):e37205. PubMed ID: 22606351
[TBL] [Abstract][Full Text] [Related]
20. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.
Cornelison AM; Kantarjian H; Cortes J; Jabbour E
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(0 1):S101-10. PubMed ID: 22035738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
